Videos

Lee Schwartzberg, MD, discusses important questions that have been raised due to the positive results of pembrolizumab immunotherapy for patients with triple-negative breast cancer.

Expert perspectives on the nature and occurrence of graft-versus-host disease alongside available prophylactic regimens.

Jennifer Brown, MD, PhD discusses the purpose of the SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia.

Tycel Phillips, MD, discusses the potential use of glofitamab as therapy for patients with relapsed/refractory mantle cell lymphoma.

Charles Geyer, MD, discusses olaparib for the treatment of patients with BRCA-positive, HER2-negative high-risk early breast cancer as evaluated in the OlympiA study.

Lyudmila Bazhenova, MD, discusses targeted therapies for patients with KRAS-mutated non–small cell lung cancer.

Closing out his discussion, Yi-Bin Chen, MD, talks about unmet needs, ongoing clinical trials, emerging treatment options for patients with steroid-refractory chronic GVHD.

Yi-Bin Chen, MD, reflects on the patient case and outlines strategies for educating and managing patients at risk of developing chronic GVHD.

A brief overview of safety and adverse events in the REACH3 trial of ruxolitinib in patients with steroid-refractory chronic GVHD.

A discussion of data from the REACH3 trial and real-world data on the efficacy of ruxolitinib in patients with steroid-refractory chronic GVHD.

Yi-Bin Chen, MD, discusses available treatment options for patients with steroid-refractory chronic GVHD.

Insight on early diagnosis of chronic GVHD and the tools clinicians use to assess GVHD severity.

A comprehensive overview of the symptoms of and organs involved in chronic GVHD.

Nicholas J. Vogelzang, MD, discusses some of the approvals and different regimens seen in today’s renal cell carcinoma treatment landscape.

A focused discussion on various risk factors for developing chronic GVHD and steroid-refractory disease.

Yi-Bin Chen, MD, discusses the work-up, diagnosis, and treatment of a 42-year-old woman with moderate steroid-refractory chronic graft-versus-host disease (GVHD).

Michael Chuong, MD, discusses the unmet needs for the treatment of inoperable pancreatic cancer.

John Marshall, MD, discusses the DESTINY-Gastric01 study of fam-trastuzumab deruxtecan-nxki in patients with locally advanced or metastatic HER2-positive gastric cancer.

Afshin Dowlati, MD, discusses treatment decision-making for patients with late-stage small cell lung cancer.

Michael Wang, MD, discusses the study design of the ongoing, multicenter, open-label study examining an acalabrutinib triplet in MCL.

Theodore W. Laetsch, MD, discusses various trials examining larotrectinib in patients with TRK fusion positive thyroid cancer.

Bhavana Pothuri, MD, discusses ongoing and potential studies of copy-number low and high subgroups of patients with endometrial cancer.

Annelise Wilhite, MD, explains what current treatment options look like for patients with vulvar/vaginal melanoma.

Afshin Dowlati, MD, discusses the targeted therapies available for patients with EGFR-mutated late-stage non–small cell lung cancer.

Solange Peters, MD, PhD, discusses the ways in which oncologists can manage toxicities in patients with unresectable malignant pleural mesothelioma.

Richard D. Carvajal, MD, discusses the mechanism of action and efficacy of tebentafusp-tebn for patients with uveal melanoma.

Discussing future needs and investigating novel therapies for newly diagnosed metastatic renal cell carcinoma.

An overview of data demonstrated by other investigational studies of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.

Implications for treating patients with metastatic renal cell carcinoma with frontline lenvatinib plus pembrolizumab based on the regimen’s performance in the CLEAR study compared with other treatment options.

Dr Moshe Ornstein examines dosing considerations for the combination of lenvatinib plus pembrolizumab in clinical practice and how that compares with the findings from the CLEAR study.